Atlas Trials

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Clinical trial NCT06340360 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06340360
Sponsor
Nektar Therapeutics
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Alopecia Areata
Start date
2024-04-02
Primary completion
2025-11-26
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.